Moore Capital Management LP Acquires New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Moore Capital Management LP bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the 3rd quarter, HoldingsChannel.com reports. The fund bought 21,247 shares of the biopharmaceutical company’s stock, valued at approximately $4,253,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Guardian Wealth Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $27,000. Allworth Financial LP boosted its stake in Alnylam Pharmaceuticals by 708.7% during the third quarter. Allworth Financial LP now owns 186 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 163 shares during the period. SeaCrest Wealth Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at about $44,000. Alta Advisers Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $80,000. Finally, Trust Co. of Vermont purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $100,000.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 18,072 shares of the company’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $200.00, for a total value of $3,614,400.00. Following the completion of the transaction, the chief marketing officer now owns 4,345 shares in the company, valued at approximately $869,000. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, CMO Pushkal Garg sold 18,072 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the sale, the chief marketing officer now owns 4,345 shares in the company, valued at $869,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Indrani Lall Franchini sold 1,675 shares of the company’s stock in a transaction dated Thursday, February 2nd. The shares were sold at an average price of $226.01, for a total value of $378,566.75. Following the completion of the sale, the executive vice president now directly owns 3,500 shares of the company’s stock, valued at $791,035. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently weighed in on ALNY shares. Piper Sandler lifted their target price on shares of Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the company an “overweight” rating in a report on Friday, December 16th. EF Hutton Acquisition Co. I started coverage on Alnylam Pharmaceuticals in a report on Tuesday, February 21st. They issued a “buy” rating and a $304.00 price objective on the stock. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $210.00 to $205.00 and set an “equal weight” rating for the company in a report on Friday, February 24th. Canaccord Genuity Group cut their price target on shares of Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating on the stock in a research note on Friday, February 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $415.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 3rd. Seven analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $244.26.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $185.95 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $117.58 and a 12 month high of $242.97. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.51 and a quick ratio of 3.34. The firm has a market capitalization of $23.08 billion, a PE ratio of -20.02 and a beta of 0.49. The business’s fifty day moving average price is $218.64 and its 200 day moving average price is $214.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its quarterly earnings data on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.45. The business had revenue of $335.04 million for the quarter, compared to the consensus estimate of $312.45 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 109.04%. The business’s revenue for the quarter was up 29.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.16) EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.78 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.